Sublingual Immunotherapy (SLIT) for U. S. Naval Hospital Yokosuka, Japan
Closed Pre-Solicitation Posted
- Solicitation number
- HT941024N0065
- Agency
-
Defense Health Agency
Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- Not on record
- Place of performance
- Yokosuka Kagawa Japan
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
Paragraph 1:
The Defense Health Agency Contracting Activity (DHACA) intends to award a firm fixed price sole source contract for Sublingual Immunotherapy (SLIT) consumables to support the U.S. Naval Hospital Yokosuka in Japan. The contract will include a base year and four one-year options, with 120 vials of SLIT consumables to be delivered each year. The objective is to provide uninterrupted operational support for the hospital. Allergy Choices, Inc. is the only source able to meet the government's minimum requirements. Interested vendors must submit capability statements by May 24, 2024 demonstrating their ability to provide the required services.
Paragraph 2:
This procurement is not set aside for any particular business type. Based on market research, Allergy Choices, Inc. is the only potential contractor identified. The total contract value across the base year and four options is not specified. The North American Industry Classification System (NAICS) code is 325412 - Pharmaceutical Preparation Manufacturing, with a business size standard of 1,300 employees. The Product Service Code (PSC) is 6505 - Drugs and Biologicals.
Notice text
Notice of Intent to Sole Source
HT941024N0065
THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE SUPPLY CONTRACT AND IS NOT A REQUEST FOR COMPETITIVE QUOTES. The Defense Health Agency Contracting Activity (DHACA), Western Markets Contracting Division (WMCD), San Diego, intends to negotiate and award a firm fixed price contract for Sublingual Immunotherapy (SLIT) from Allergy Choices, Inc. in accordance with Federal Acquisition Regulation (FAR) 13.106-1(b)(1)(i), only one source being available to meet the Government’s needs, to:
Allergy Choices, Inc.
2731 National Dr.
Onalaska, WI 54650-8784
The North American Industry Classification System (NAICS) code for this requirement is 325412 – Pharmaceutical Preparation Manufacturing; the business size standard is 1,300 employees. The Product Service Code (PSC) is 6505 – Drugs and Biologicals.
The US Naval Hospital Yokosuka provides medical readiness for U.S. Pacific Fleet. Having a dedicated contracted SLIT support for US Naval Hospital Yokosuka will allow uninterrupted operational support for the waterfront.
The objective of this sole source award is to procure SLIT consumables (listed below). Allergy Choices, Inc.
doesn’t have distributors for their products and ship directly to consumers.
Consumables:
Item#
Description
QTY (EA)
Ultimate Delivery Date
Base Year
Inhalant (red) Mult-Allergen
1-20 Antigens One 15Mil Vial (90 Day Sypply)
120
9/30/2025
Option 1
Inhalant (red) Mult-Allergen
1-20 Antigens One 15Mil Vial (90 Day Sypply)
120
9/30/2026
Option 2
Inhalant (red) Mult-Allergen
1-20 Antigens One 15Mil Vial (90 Day Sypply)
120
9/30/2027
Option 3
Inhalant (red) Mult-Allergen
1-20 Antigens One 15Mil Vial (90 Day Sypply)
120
9/30/2028
Option 4
Inhalant (red) Mult-Allergen
1-20 Antigens One 15Mil Vial (90 Day Sypply)
120
9/30/2029
SHIP TO ADDRESS: US Naval Hospital Yokosuka JAPAN:
US Naval Hospital Yokosuka
Attention : Otolaryngology Department
PSC 475 Box 6
FPO AP 96350-1600
Based on market research, Allergy Choices, Inc., is the only source that can meet the Government’s minimum requirements for the SLIT consumables from Allergy Choices, Inc. at US Naval Hospital Yokosuka
This notice of intent is not a request for competitive proposals, and no solicitation document exists for this requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data and cost information, in sufficient detail and with convincing evidence that clearly demonstrates the capability to provide the required services for US Naval Hospital Yokosuka. Capability statements shall not exceed six (8.5 x 11 inch) pages using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source purchase order.
If a vendor challenges the basis of this requirement, please email capability statements as a Microsoft Word or Adobe PDF attachment to Marcela Cervantes at marcela.cervantes.civ@health.mil. The closing date for challenges is no later than 11:00 Pacific Time, 24 May 2024.
NO TELEPHONE REQUESTS/OFFERS WILL BE HONORED.
Files
| File | Type | Posted |
|---|---|---|
| Notice of Intent to Sole Source - SLIT 9 May.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| This notice | Pre-Solicitation | |
| Sublingual Immunotherapy (SLIT) for U. S. Naval Hospital Yokosuka, Japan | Special Notice |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity